Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9815064 | 0.86 | BRD4 (0.39) | BRD4BRD2 | |
| SCHEMBL23642177 | 0.86 | BRD4 (0.39) | BRD4BRD2 | |
| SCHEMBL611663 | 0.84 | POLB (0.35) | POLB | |
| SCHEMBL12724765 | 0.78 | BRD4 (0.31) | BRD4BRD2POLB | |
| SCHEMBL14459661 | 0.78 | — | — | |
| SCHEMBL22525723 | 0.78 | PIK3CD (0.48) | — | |
| SCHEMBL24926127 | 0.78 | HRH3 (0.33) | — | |
| SCHEMBL25237449 | 0.76 | — | — | |
| SCHEMBL28956006 | 0.76 | — | — | |
| SCHEMBL2398125 | 0.74 | BRD4 (0.43) | BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230111914-A1 | SYNTHETIC TRITERPENOIDS WITH NITROGEN-BASED SUBSTITUENTS AT C-17 AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2023004163-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-0280781-B1 | PROCESS FOR THE PREPARATION OF N-ALKYL-N'-METHYL-CYCLIC UREAS, ESPECIALLY N,N'-DIMETHYLCYCLIC UREAS | HÜLS AKTIENGESELLSCHAFT (DE) | 1991-09-18 | — | — | EP | disclosed |
| US-4864026-A | Method of manufacturing N-alkyl-N'-methyl-alkyleneureas, particularly N,N'-d | HULS AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280781-A1 | Process for the preparation of N-alkyl-N'-methyl-cyclic ureas, especially N,N'-dimethylcyclic ureas | HÜLS AKTIENGESELLSCHAFT (DE) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | BRD4 1289/4885BRD2 1369/4885POLB 4309/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | BRD4 2616/4885BRD2 2313/4885POLB 4427/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | BRD4 2/4885BRD2 26/4885POLB 594/4885 |
| US-20230111914-A1 | SYNTHETIC TRITERPENOIDS WITH NITROGEN-BASED SUBSTITUENTS AT C-17 AND METHODS OF USE THEREOF | CYP11B1, CYP11B2, IL17A | BRD4 1948/4885BRD2 3622/4885POLB 884/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | BRD4 3384/4885BRD2 3672/4885POLB 1063/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | BRD4 3/4885BRD2 6/4885POLB 453/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | BRD4 562/4885BRD2 364/4885POLB 1390/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | BRD4 613/4885BRD2 1299/4885POLB 490/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | BRD4 1289/4885BRD2 1369/4885POLB 4309/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | BRD4 562/4885BRD2 364/4885POLB 1390/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | BRD4 2620/4885BRD2 2305/4885POLB 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.